Therapeutics News and Research

RSS

BioWa, NKT Therapeutics sign licensing agreement

BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they have entered into an agreement which provides NKTT with access to BioWa's patented POTELLIGENT(®) Technology platform for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

21 Oct 2009

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues.

21 Oct 2009

NIH grant for Lpath to advance clinical development of its antibody therapeutics

The National Cancer Institute's Small Business Innovation Research (SBIR) Program has awarded Lpath (OTCBB: LPTN), the category leader in lipidomics-based therapeutics, two Phase 1 grants totaling $0.3 million. This follows a series of other SBIR grants awarded to Lpath totaling $6.9 million, including a $3.0 million Phase 2 bridge grant from the NCI awarded this past June.

21 Oct 2009

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

Pfizer announces first recipient of its Ripples of Hope Trainee Award in Mental Health

Pfizer Canada is pleased to announce Valeria Uribe as the first recipient of the newly established Pfizer Ripples of Hope Trainee Award in Mental Health. Ms. Uribe is currently working towards a Masters in Science at the University of British Columbia in her pursuit of a career in neuroscience.

21 Oct 2009

GlycoMimetics raises $38 million through venture financing

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Unigene Laboratories, Inc. and Tarsa Therapeutics, Inc. today announced that Unigene has licensed its Phase III oral calcitonin program to Tarsa, a new company formed by a syndicate of three venture capital funds specializing in the life sciences: MVM Life Science Partners, Quaker BioVentures and Novo A/S.

20 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Unemployed nurses are switching to RN health coach careers

Although the contagious economic epidemic is killing off nursing jobs, the thriving RN health coach sector appears to be immune. Many underpaid or unemployed nurses are transitioning into the booming health coach field with help from L.I.T.E. Therapeutics -- a leading provider of health coaches with nursing backgrounds.

20 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

Cumberland Pharmaceuticals Inc. announced today that its Phase III study on intravenous ibuprofen as a post-operative analgesic was published in Volume 31, Number 9 of the peer-reviewed journal Clinical Therapeutics, distributed in October. The study concludes that patients emerging from orthopedic and abdominal surgeries required less narcotic and experienced less pain with 800 mg of intravenous ibuprofen every six hours compared to morphine alone.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. for a joint collaboration to develop novel ion channel drugs.

20 Oct 2009

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Winston Laboratories, Inc. (“Winston Labs”), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced that it has received a Notice of Non-compliance (“NON”) from the Therapeutics Drug Directorate, Health Canada (the “Directorate”) for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Amylin Pharmaceuticals, Inc. today announced that new data from its obesity program will be presented at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society, to be held in Washington, D.C. October 24-28. Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation.

20 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).

19 Oct 2009

Therapeutics News and Research

BioWa, NKT Therapeutics sign licensing agreement

CI Index of cancer immunotherapy stocks increases 80% during quarter; two companies lead CI index

NIH grant for Lpath to advance clinical development of its antibody therapeutics

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Logical Therapeutics to present its clinical study results on LT-NS001

Pfizer announces first recipient of its Ripples of Hope Trainee Award in Mental Health

GlycoMimetics raises $38 million through venture financing

Positive results from KAI Pharmaceuticals' pain therapeutic program

Tarsa Therapeutics receives license for Phase III oral calcitonin program

Targacept presents data from Phase 2b clinical trial of TC-5214

Unemployed nurses are switching to RN health coach careers

ImmunoCellular Therapeutics files a provisional patent application

Cumberland Pharmaceuticals publishes data on its Phase III intravenous ibuprofen study

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Amylin Pharmaceuticals to present new data from its obesity program at Obesity 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News